vh4524184
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 21, 2022 (NCT05631704)
Timeline
Indications
Studied for
Mechanism of action
Q7ZJM1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07202546 | Phase 2 | Nov 28, 2025 | ViiV Healthcare |
| NCT07066722 | Phase 1 | Jul 7, 2025 | ViiV Healthcare |
| NCT06310551 | Phase 1 | Mar 21, 2024 | GlaxoSmithKline, ViiV Healthcare |
| NCT06310616 | Phase 1 | Mar 6, 2024 | ViiV Healthcare |
| NCT06214052 | Phase 2 | Feb 7, 2024 | GlaxoSmithKline, ViiV Healthcare |
| NCT05631704 | Phase 1 | Nov 21, 2022 | ViiV Healthcare |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ViiV Healthcare | For profit | 6 | 6 | 2 | 2022 |
| GlaxoSmithKline | For profit | 2 | 0 | 2 | 2024 |
2 organizations
Page 1 / 1